STMN2 has been profiled in early-stage liver fibrosis in patients with chronic hepatitis C virus infection [28], and its expression has been positively correlated with insulin resistance in NASH [29]. Here, STMN2 is linked to metabolic dysfunction-associated steatohepatitis.